Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Sea Otter who wrote (705)	4/16/1999 1:07:00 AM
From: Sea Otter	Read Replies (1) \| Respond to of 2515

From the interview ... "1/3 of all cancers express the C-225 target. Huge revenue opportunity" [Translation: when combined with radiation/chemo, next year IMCL will have a complete cure for 1/3 of all cancers]. The CEO seemed completely confident about C-225 approval. I think he is telegraphing early Phase III results. Everyone should listen to this interview. He did an excellent job making the IMCL case, in a very substantive way (cured rats weren't mentioned once). It's a wonder this stock hasn't broken into the stratosphere. Ok with me. I'm happy to keep accumulating. My weekly Friday end-of-day-buy comes up tomorrow ...